WO2026098196 discloses engineered #Ecteinascidin-derived cytotoxic payloads for #ADC therapeutics. By adding linker sites, hydrophilic/amino substituents and cleavable spacers, the compounds improve stability, PK, tumour selectivity and therapeutic window while reducing systemic toxicity in vivo.
May 27, 2026 at 10:55 AM
WO2026098196 discloses engineered #Ecteinascidin-derived cytotoxic payloads for #ADC therapeutics. By adding linker sites, hydrophilic/amino substituents and cleavable spacers, the compounds improve stability, PK, tumour selectivity and therapeutic window while reducing systemic toxicity in vivo.